Sociedad Americana de Hirudoterapia

The pharmacology of extinction

Review published in Journal of ethnopharmacology (1992)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosHuxtable RJ · Journal of ethnopharmacology, 1992

Abstract

It is impossible to predict what compounds of pharmacological interest may be present in an unexamined species. The extinction of such species may result, therefore, in the loss of therapeutically significant compounds. The fact that science will never know what has been lost does not lessen the significance of the loss. A number of species are discussed to exemplify the potential loss. Ginkgo biloba is an ancient plant, apparently saved from a natural extinction by human intervention. From this tree, the ginkgolides have been isolated. These are potent inhibitors of platelet activating factor and hold promise in the treatment of cerebral ischemia and brain edema. Two species, the tree Taxus brevifolia and the leech Hirudo medicinalis, are threatened as a result of human activity. Both have recently yielded complex compounds of therapeutic importance. The antitumor agent, taxol, is obtained from T. brevifolia and the thrombin inhibitor, hirudin, is found in H. medicinalis. Catharanthus roseus, source of the anticancer agents vincristine and vinblastine, although not threatened, derives from a largely unexamined but severely stressed ecosystem of some 5000 plant species. In other examples, ethnobotanical knowledge of certain plants may be lost while the species survive, as exemplified by the suppression of the Aztec ethnobotany of Mesoamerica by the invading Spanish. Finally, the fallacy of the 'snail darter syndrome', where species may be viewed as too insignificant to worry about, is exposed by consideration of the pharmacological activities of a sea hare (a shell-less marine mollusc) and various leeches.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsEcologyMedicine, TraditionalPlants, MedicinalTissue Extracts

Resumen

It is impossible to predict what compounds of pharmacological interest may be present in an unexamined species.

Por qué esto importa para la hirudoterapia

This review discusses how species extinction may result in the loss of therapeutically significant compounds, citing multiple examples including Ginkgo biloba (ginkgolides), Taxus brevifolia (taxol), Catharanthus roseus (vincristine, vinblastine), and the leech Hirudo medicinalis (hirudin). It identifies H. medicinalis as a species threatened by human activity that has yielded hirudin, a thrombin inhibitor of therapeutic importance, and references the pharmacological activities of various leeches as further examples. For ASH's domain, this is relevant insofar as it frames medicinal leeches as a source of bioactive therapeutics and underscores the conservation significance of leech biodiversity. The caveat is that this is a broad narrative review rather than an empirical study, and it provides no original data on hirudotherapy or leech-derived compounds beyond hirudin.

Citación

The pharmacology of extinction

Huxtable RJ · Journal of ethnopharmacology, 1992

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.